Introduction
============

Liver failure (LF) is a complex medical emergency that evolves following a catastrophic insult to the liver with an outcome that remains the most ominous of all the gastroenterologic diseases. LF is severe liver damage resulting from various factors, which cause obstruction or decompensation of function, such as composition, detoxifιcation, drainage and biotransformation. Various clinical syndromes appear, including the obstruction of coagulation mechanisms, icterus, hepatic encephalopathy and ascites. Serious complications, such as hepatic encephalopathy and renal inadequacy tend to occur during the course of the disease and further exacerbate clinical syndromes. It is conventionally defined by an arterial oxygen tension (P~a~O~2~) \<8.0 kPa (60 mmHg) and/or an arterial carbon dioxide tension (P~a~CO~2~) \>6.0 kPa (45 mmHg), and a serum bilirubin level ≥12.0 mg/dl. The prognosis of patients with severe liver injury, particularly with LF, largely depends upon the regenerative capacity of hepatocytes during comprehensive treatment. Liver transplantation improves survival and quality of life. However, treatment is futile in certain patients, but it is difficult to identify these patients a priori. In clinical practice, serum α-fetoprotein is often used as a predictive biomarker for monitoring the prognosis of patients with LF, as it reflects the regeneration of hepatocytes in response to liver injury ([@b1-br-0-0-835]--[@b3-br-0-0-835]). Although the most important function of telomerase is associated with cell proliferation and regeneration, to the best of our knowledge, there are no studies regarding the association of the prognosis of LF and telomerase activation. Thus, identification of molecular markers is required and novel treatments against this disease must be developed. In addition, improved non-invasive methods of detecting LF are urgently required in order to influence the survival of the increasing numbers of individuals affected by this disease.

The precise molecular pathogenic mechanism of LF remains unknown. Development of biomarkers for a deeper understanding of LF pathogenesis and improving diagnosis, prognosis, and treatment remains one of the main goals and challenges in LF research. Biomarkers within the blood and urine reflect the status and possible future progression of a disease ([@b4-br-0-0-835]). Aberrant functions of the lymphocytic regulatory pathway are extensively involved in the pathological mechanism of certain diseases ([@b5-br-0-0-835]); therefore, peripheral blood mononuclear cells (PBMCs) are an attractive sample source in such studies. Proteomic analysis is a research method that catalogs all of the proteins within cells and organisms. Recent advancements in quantitative and large-scale proteomic methods may be used to optimize the clinical application of biomarkers ([@b6-br-0-0-835]). Furthermore, advancements of proteomic techniques contribute to the identification of clinically useful biomarkers and clarify the molecular mechanisms of disease pathogenesis using body fluids, such as serum, as well as tissue samples and cultured cells.

Proteomics analysis is a powerful technology used in a myriad of studies, including those focused on liver diseases ([@b7-br-0-0-835]--[@b11-br-0-0-835]). The isobaric tags for relative and absolute quantitation (iTRAQ) method allows a more comprehensive analysis. This method has a high sensitivity and it is possible to detect low-abundance proteins. iTRAQ has increasingly been applied in biomarker research in various sample sources for various disease states ([@b12-br-0-0-835]--[@b14-br-0-0-835]). Charlton *et al* ([@b15-br-0-0-835]) compared the protein expression profiles in four groups of liver tissue samples from obese patients using the combination of iTRAQ with liquid chromatography (LC)-mass spectrometry (MS)/MS. The authors identified a total of 1,362 hepatic-expressed proteins, and identified two important proteins. Niu *et al* performed various *in vitro* proteomic investigations of Hepatitis B virus (HBV)-infected HepG2 hepatoma cells to evaluate the protein changes associated with the virus infection. Using the combined methods of iTRAQ with 2D-LC-MS/MS, the authors compared the protein expression in non-infected HepG2 with that in HBV-infected HepG2 cells to identify various proteins that were downregulated in the HBV-infected cells, including S100 calcium-binding protein A6 and Αnnexin A2 ([@b16-br-0-0-835],[@b17-br-0-0-835]).

In the present study, iTRAQ technology was used to analyze the total proteins in PBMCs of LF patients. The aim was to identify the differences in PBMC protein levels that were closely associated with the progression of LF. Further investigation into the molecular mechanism of the proteins involved may improve understanding of the pathogenesis of LF and facilitate development of novel approaches to diagnose and treat LF.

Materials and methods
=====================

### Main reagents

Triton X-100 was purchased from GE Healthcare (Waukesha, WI, USA). Triethylammonium bicarbonate buffer was acquired from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). ZipTip Pipette Tips and Milli-Q water were obtained from EMD Millipore (Billerica, MA, USA). The iTRAQ Reagent-8 Plex Multiplex kit was acquired from Applied Biosystems (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Strata-X 33 Polymeric Reversed Phase was purchased from Phenomenex (Los Angeles, CA, USA). All other reagents were acquired from commercial sources.

### Patients and healthy controls

Ten patients (6 male and 4 female; aged 23--57 years) were diagnosed as LF between January and December 2014, and 10 age- and gender-matched subjects were recruited as healthy controls. HBV-associated LF refers to patients with LF caused by chronic HBV infection. The 10 patients and 10 healthy control subjects were from Shenzhen People\'s Hospital (Shenzhen, China). The diagnosis of LF was confirmed by pathologic diagnosis and clinical evidence.

The control subjects were recruited and a general health checkup program confirmed that there was no clinical evidence of LF. All participants were informed of their participation rights and written informed consent was obtained. The present study was performed in accordance with the Helsinki Declaration and approved by the Regional Ethics Committee.

### PBMC isolation, protein extraction and quantitation

One 10-ml fasting venous blood sample was collected in heparinized vacutainers from each enrolled subject. PBMCs were isolated with lymphocyte-H medium (Cedarlane Labs, Hornby, ON, Canada) according to the manufacturer\'s instruction. The total protein of PBMCs was extracted, and their concentration was measured using a BCA protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instruction. The proteins in the supernatant were maintained at −80°C for further analysis.

### iTRAQ labeling and strong cation exchange (SCX) chromatography fractionation

Total protein (100 µg) from the PBMCs of the 10 LF patients and 10 healthy control subjects was digested separately with Trypsin Gold (Promega Corporation, Madison, WI, USA) with the ratio of protein:trypsin 30:1 at 37°C for 16 h. Following trypsin digestion, peptides were dried by vacuum centrifugation at 2,000 × g at room temperature for 10 min. Peptides were reconstituted in 0.5 M triethyl-ammonium bicarbonate buffer and processed according to the manufacture\'s protocol for the 8-plex iTRAQ reagent. Briefly, one unit of iTRAQ reagent was thawed and reconstituted in 24 µl isopropanol. Samples were labeled with the iTRAQ tags as follows: Sample 113 and sample 115. The peptides were labeled with the isobaric tags and incubated at room temperature for 2 h. The labeled peptide mixtures were then pooled and dried by vacuum centrifugation at 2,000 × g at room temperature for 10 min.

SCX chromatography was performed with a LC-20AB high-performance LC (HPLC) Pump system (Shimadzu Corp., Kyoto, Japan). The iTRAQ-labeled peptide mixtures were reconstituted with 4 ml buffer A (25 mM NaH~2~PO~4~ in 25% ACN, pH 2.7) and loaded onto a 4.6×250 mm Ultremex SCX column containing 5-µm particles (Phenomenex). The peptides were eluted at a flow rate of 1 ml/min with a gradient of buffer A for 10 min, 5--60% buffer B (25 mM NaH~2~PO~4~, 1 M KCl in 25% ACN, pH 2.7) for 27 min and 60--100% buffer B for 1 min. The system was then maintained at 100% buffer B for 1 min before equilibrating with buffer A for 10 min prior to the next injection. Elution was monitored by measuring the absorbance at 214 nm with ultraviolet-visible spectrophotometry, and fractions were collected at 1-min intervals. The eluted peptides were pooled into 20 fractions, desalted with a Strata X C18 column (Phenomenex) and vacuum-dried.

### LC-MS/MS analysis based on Q-EXACTIVE

Each fraction was resuspended in buffer A (2% ACN, 0.1% FA) and centrifuged at 20,000 × g for 10 min at 4°C, the final concentration of peptide was \~0.5 µg/µl on average. Supernatant (10 µl) was loaded onto an LC-20AD nano HPLC (Shimadzu Corp., Kyoto, Japan) by the autosampler onto a 2-cm C18 trap column (inner diameter, 200 µm). Then, the peptides were eluted onto a 10-cm analytical C18 column (inner diameter, 75 µm) packed in-house. The samples were loaded at 8 μl/min for 4 min, then the 44-min gradient was run at 300 nl/min starting from 2 to 35% solvent B (98% ACN, 0.1% fatty acid), followed by a 2-min linear gradient to 80% and maintenance at 80% solvent B for 4 min, and finally returning to 5% in 1 min.

The peptides were subjected to nanoelectrospray ionization followed by MS/MS in a Q-EXACTIVE (Thermo Fisher Scientific, Inc.) coupled online to the HPLC. Intact peptides were detected in the orbitrap (Thermo Fisher Scientific, Inc.) at a resolution of 70,000. Peptides were selected for MS/MS using high-energy collision dissociation operating mode with a normalized collision energy setting of 27.0; ion fragments were detected in the orbitrap at a resolution of 17,500. A data-dependent procedure that alternated between one MS scan followed by 15 MS/MS scans was applied for the 15 most abundant precursor ions above a threshold ion count of 20,000 in the MS survey scan with a subsequent dynamic exclusion duration of 15 sec. The electrospray voltage applied was 1.6 kV. Automatic gain control (AGC) was used to optimize the spectra generated by the orbitrap. The AGC target for full MS was 3e6 and 1e5 for MS2. For the MS scans, the mass to charge ratio (m/z) scan range was 350--2,000 Da, and for the MS2 scans, the m/z scan range was 100--1,800.

### Western blot analysis

The protein abundance of the pooled samples previously analyzed by iTRAQ LC-MS/MS was confirmed essentially as previously described using western blotting ([@b18-br-0-0-835]). Four protein samples (35 µg) were added into electrophoretic buffer containing β-mercaptoethanol prior to SDS-PAGE. GAPDH (Kangcheng, Shanghai, China) served as a loading control. The primary antibody (dilution, 1:250; cat. no. ab89835) for ADP-ribosylation factor 1 was obtained from Abcam (Cambidge, MA, USA) and the peroxidase-conjugated goat anti-rabbit IgG secondary antibody (dilution, 1:10,000) was obtained from SouthernBiotech (Birmingham, AL, USA; cat. no. A21020). The band intensity of western blot analysis was repeated three times using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

### Statistical analysis

Protein identification was performed using Mascot version 2.3.02 (Matrix Science, London, UK). Peptide sequences were searched against the non-redundant National Center for Biotechnology Information database. For protein quantitation, it was required that a protein contained at least two unique peptides. The quantitative protein ratios were weighted and normalized by the median ratio in Mascot. Only ratios with P\<0.05 and fold-change \>1.2 were considered to be statistically significant. Search criteria were set to permit a maximum of 1 missed cleavage. The following peptide modifications were also allowed: Gln→pyro-Glu, iTRAQ 8plex, Phospho. Automatic isotope correction was performed using the two software packages using the values supplied with the Applied Biosystems reagents. The PANTHER database (<http://www.pantherdb.org/panther/>) was then used to establish the molecular function, biological process and signaling pathway associated with each individual protein. GO and KEGG pathway mapping were performed by web-accessible DAVID annotation system (version 6.7; <https://david-d.ncifcrf.gov/>).

Results
=======

### Protein expression profile

Compared with the control group, a total of 627 differently expressed proteins were detected, of which 409 proteins showed increased expression levels and 218 proteins showed decreased expression levels in LF ([Table I](#tI-br-0-0-835){ref-type="table"}). The protein ratio distribution of these proteins is illustrated in [Fig. 1](#f1-br-0-0-835){ref-type="fig"}. Relative quantification of proteins was based on the ratio of peak areas from the MS/MS spectra, and the m/z of LF patients and control subjects were involved in the present study.

### Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis

The functions of the differently expressed proteins were analyzed using the GO and KEGG pathways annotation system. The proteins produced a total of 420 GO terms in the LF group ([Table II](#tII-br-0-0-835){ref-type="table"}), including 284 in biological process, 74 in cellular component and 62 in molecular function. The results indicate that a set of highly abundant and significantly differentially expressed proteins may promote the progression of LF patients. In addition, 14 KEGG pathways of the differently expressed proteins in LF were obtained ([Table III](#tIII-br-0-0-835){ref-type="table"}).

### Western blot analysis

Four proteins, acylaminoacyl-peptide hydrolase (APEH; 1.309), WW domain binding protein 2 (WBP2; 1.385), resistin (0.747) and tubulin β 2A class IIa (TUBB2A; 0.764), were selected from the 627 proteins with variable expression levels. These differently expressed proteins between the LF and control groups were verified by western blotting ([Table IV](#tIV-br-0-0-835){ref-type="table"} and [Fig. 2](#f2-br-0-0-835){ref-type="fig"}), which indicated a similar relative expression level when compared with the iTRAQ LC-MS/MS analysis.

Discussion
==========

Protein quantification has become an important and, in many cases, critical component of modern MS-based proteomic research ([@b19-br-0-0-835],[@b20-br-0-0-835]). Proteomics is the term used for exhaustive analysis of protein structure and function. It is useful for elucidation of the pathology and identification of disease markers for liver diseases. PBMCs are often used as clinical samples, rather than tissue, as less invasive methods may be used to obtain them. If a biomarker associated with the pathology, disease progression or efficacy of treatment is identified in PBMCs, it may be easily applied for early or differential diagnosis of diseases. Of these, iTRAQ, which enables the parallel comparison of protein abundance by measuring the peak intensities of reporter ions released from iTRAQ-tagged peptides, has the potential to be a key tool in the area of quantitative proteomic study. In the current study, iTRAQ technology was adopted to quantitatively analyze the proteomics of PBMCs from LF patients and healthy control subjects. As a result, 627 proteins involving different biological functions and cellular locations were identified. Among these proteins, four proteins were significantly differentially expressed; APEH and WBP2 were upregulated, and resistin and TUBB2A were downregulated. It provided additional proof that the iTRAQ technique accurately quantifies relative changes in protein abundance of PBMCs, which has been demonstrated to be useful in detecting pathological stages or prognosis in certain diseases, such as osteoarthritis ([@b21-br-0-0-835],[@b22-br-0-0-835]).

Resistin is cysteine-rich protein belonging to the RELM family. The genetic structure of the *Retn* gene varies between mammals and the similarity in the coding sequence ranges from \~60% for rodents to 80% for livestock ([@b23-br-0-0-835]). The expression of this gene in rodents occurs predominantly in mature adipocytes, although it was also identified in other tissues. Retn is considered to be a factor linking obesity and insulin resistance. In obesity, its expression increases, leading to enhanced resistance of tissues to insulin ([@b24-br-0-0-835]). *TUBB2A* is thought to comprise \~30% of all β-tubulin within the brain ([@b25-br-0-0-835]) and contributes to the growing list of tubulin gene mutations that are associated with impaired brain development in humans. Increased expression levels of *TUBB2A* have been correlated with decreased drug sensitivity in paclitaxel-resistant cell lines ([@b26-br-0-0-835]). A previous study demonstrated the potential of a model for gene perturbation studies by demonstrating that decreased expression levels of *TUBB2A* result in significantly increased sensitivity of neurons to paclitaxel ([@b27-br-0-0-835]).

The role of WBP-2 is as a coactivator for estrogen receptor and progesterone receptor transactivation pathways ([@b28-br-0-0-835]). APEH has been postulated to serve as a key regulator of N-terminal acetylated proteins ([@b29-br-0-0-835]). As \>80% of proteins in human cells are N-terminal acetylated ([@b30-br-0-0-835],[@b31-br-0-0-835]) and protein acetylation is implicated in a variety of essential cellular pathways ([@b32-br-0-0-835]), it is feasible that APEH is involved in these processes. APEH, one of the four members of the prolyl oligopeptidase class, catalyses the removal of N-acetylated amino acids from acetylated peptides and it has been postulated to be key in protein degradation machinery. Disruption of protein turnover has been established as an effective strategy to downregulate the ubiquitin proteasome system and as a promising approach in anticancer therapy. APEH may be an upstream modulator of the proteasome ([@b33-br-0-0-835]).

To establish the biological roles of the proteins from LF, GO enrichment and KEGG pathway analyses were performed. GO categories were separated into three groups: Molecular function, biological process and cellular component. The present study identified GO terms for molecular function significantly enriched in protein binding (GO:0005515; P=0.02145) involving *TUBB2A* and WBP2, and for cellular component, the enriched GO terms were cytoplasm (GO:0005737; P=0.02634) involving APEH and TUBB2A. KEGG analysis was performed with P\<0.05 as the criteria for significant pathway identification. The significant pathway in the KEGG analysis was identified as phagosome (P=0.02839) involving TUBB2A. Phagocytosis is the process of a cell taking in relatively large particles, and is a central mechanism in tissue remodeling, inflammation and defense against infectious agents. A phagosome is formed when the specific receptors on the phagocyte surface recognize ligands on the particle surface. Following formation, nascent phagosomes progressively acquire digestive characteristics.

In conclusion, proteomic technologies based on MS have been developed, and the reliability of these technologies continues to improve. Such advancements in proteomic techniques may contribute to the identification of clinically useful biomarkers and the elucidation of the molecular mechanisms involved in disease pathogenesis. Therefore, a more sensitive detection system to search for biomarkers is required, and this may allow clinically useful markers for all liver diseases to be identified. Proteins are assumed to be key molecules that define the characteristics and dynamics of cells, and control biological reactions. Therefore, investigation of changes in protein expression levels is particularly important in understanding disease pathology. A limitation of the current study is that it did not discuss each of the candidate proteins in detail. The aim of this preliminary study was to focus on delineating primary comparative protein profiles of LF patients and healthy control subjects using iTRAQ technology. In future, a large-scale clinical study is required to investigate useful biomarkers of LF. This may result in a novel method for diagnosing LF. In addition, the current study demonstrates the potential application of iTRAQ-based quantitative proteomics for identifying protein changes and detecting notable biomarker candidates in certain diseases. Thus, identification and evaluation of an easily measurable biomarker is imperative. A combination of conventional markers with newly identified markers, the variation of which was confirmed in the present study, may improve diagnosis of the LF disease state and the capacity for prognosis.
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###### 

LF proteome.

  A, Top 30 increased proteins in LF                                                                                                 
  ------------------------------------ ------------------------- ------------------------------------------------------------------- ------------------------
  1                                    sp\|P22392\|NDKB_HUMAN    Nucleoside diphosphate kinase B                                     3.953
  2                                    sp\|Q9UM07\|PADI4_HUMAN   Protein-arginine deiminase type-4                                   3.509
  3                                    sp\|Q9CQC6\|BZW1_MOUSE    Basic leucine zipper and W2 domain-containing protein 1             3.431
  4                                    sp\|Q96DA6\|TIM14_HUMAN   Mitochondrial import inner membrane translocase subunit TIM14       3.297
  5                                    sp\|P52790\|HXK3_HUMAN    Hexokinase-3                                                        2.957
  6                                    sp\|P80188\|NGAL_HUMAN    Neutrophil gelatinase-associated lipocalin                          2.928
  7                                    sp\|P25774\|CATS_HUMAN    Cathepsin S                                                         2.8
  8                                    sp\|P12429\|ANXA3_HUMAN   Annexin A3                                                          2.631
  9                                    sp\|P37837\|TALDO_HUMAN   Transaldolase                                                       2.595
  10                                   sp\|P41218\|MNDA_HUMAN    Myeloid cell nuclear differentiation antigen                        2.55
  11                                   sp\|Q9ULZ3\|ASC_HUMAN     Apoptosis-associated speck-like protein containing a CARD           2.514
  12                                   sp\|Q4R6V2\|TCPE_MACFA    T-complex protein 1 subunit epsilon                                 2.362
  13                                   sp\|P26583\|HMGB2_HUMAN   High mobility group protein B2                                      2.361
  14                                   sp\|Q9UBW5\|BIN2_HUMAN    Bridging integrator 2                                               2.355
  15                                   sp\|Q6P4A8\|PLBL1_HUMAN   Phospholipase B-like 1                                              2.339
  16                                   sp\|A6NI72\|NCF1B_HUMAN   Putative neutrophil cytosol factor 1B                               2.338
  17                                   sp\|P39687\|AN32A_HUMAN   Acidic leucine-rich nuclear phosphoprotein 32 family member A       2.295
  18                                   sp\|Q92688\|AN32B_HUMAN   Acidic leucine-rich nuclear phosphoprotein 32 family member B       2.295
  19                                   sp\|P61586\|RHOA_HUMAN    Transforming protein RhoA                                           2.292
  20                                   sp\|P20700\|LMNB1_HUMAN   Lamin-B1                                                            2.249
  21                                   sp\|O75962\|TRIO_HUMAN    Triple functional domain protein                                    2.233
  22                                   sp\|Q92905\|CSN5_HUMAN    COP9 signalosome complex subunit 5                                  2.201
  23                                   sp\|P18433\|PTPRA_HUMAN   Receptor-type tyrosine-protein phosphatase α                        2.187
  24                                   sp\|Q8BL97\|SRSF7_MOUSE   Serine/arginine-rich splicing factor 7                              2.186
  25                                   sp\|P48595\|SPB10_HUMAN   Serpin B10                                                          2.171
  26                                   sp\|P50402\|EMD_HUMAN     Emerin                                                              2.17
  27                                   sp\|O96006\|ZBED1_HUMAN   Zinc finger BED domain-containing protein 1                         2.162
  28                                   sp\|P09668\|CATH_HUMAN    Pro-cathepsin H                                                     2.146
  29                                   sp\|P50395\|GDIB_HUMAN    Rab GDP dissociation inhibitor β                                    2.1
  30                                   sp\|O73777\|IF4G2_CHICK   Eukaryotic translation initiation factor 4 γ 2 (Fragment)           2.091
                                                                                                                                     
  B, Top 30 decreased proteins in LF                                                                                                 
                                                                                                                                     
  No.                                  Accession                 Description                                                         Ratio of LF to control
                                                                                                                                     
  1                                    sp\|Q9Y2R4\|DDX52_HUMAN   Probable ATP-dependent RNA helicase DDX52                           0.078
  2                                    sp\|O75015\|FCG3B_HUMAN   Low affinity immunoglobulin gamma Fc region receptor III-B          0.211
  3                                    sp\|P12236\|ADT3_HUMAN    ADP/ATP translocase 3                                               0.277
  4                                    sp\|Q9NTG7\|SIR3_HUMAN    NAD-dependent protein deacetylase sirtuin-3, mitochondrial          0.298
  5                                    sp\|P14222\|PERF_HUMAN    Perforin-1                                                          0.346
  6                                    sp\|P20718\|GRAH_HUMAN    Granzyme H                                                          0.39
  7                                    sp\|P04264\|K2C1_HUMAN    Keratin, type II cytoskeletal 1                                     0.419
  8                                    sp\|P19086\|GNAZ_HUMAN    Guanine nucleotide-binding protein G(z) subunit α                   0.433
  9                                    sp\|P11166\|GTR1_HUMAN    Solute carrier family 2, facilitated glucose transporter member 1   0.434
  10                                   sp\|Q969X1\|LFG3_HUMAN    Protein lifeguard 3                                                 0.437
  11                                   sp\|Q15050\|RRS1_HUMAN    Ribosome biogenesis regulatory protein homolog                      0.442
  12                                   sp\|P12544\|GRAA_HUMAN    Granzyme A                                                          0.448
  13                                   sp\|P14209\|CD99_HUMAN    CD99 antigen                                                        0.45
  14                                   sp\|P07996\|TSP1_HUMAN    Thrombospondin-1                                                    0.454
  15                                   sp\|P05106\|ITB3_HUMAN    Integrin β-3                                                        0.454
  16                                   sp\|P02788\|TRFL_HUMAN    Lactotransferrin                                                    0.479
  17                                   sp\|P35527\|K1C9_HUMAN    Keratin, type I cytoskeletal 9                                      0.487
  18                                   sp\|O15533\|TPSN_HUMAN    Tapasin                                                             0.491
  19                                   sp\|O60704\|TPST2_HUMAN   Protein-tyrosine sulfotransferase 2                                 0.504
  20                                   sp\|Q9BVC6\|TM109_HUMAN   Transmembrane protein 109                                           0.506
  21                                   sp\|P37840\|SYUA_HUMAN    α-synuclein                                                         0.511
  22                                   sp\|Q08AF3\|SLFN5_HUMAN   Schlafen family member 5                                            0.514
  23                                   sp\|P16109\|LYAM3_HUMAN   P-selectin                                                          0.517
  24                                   sp\|P01871\|IGHM_HUMAN    Ig µ chain C region                                                 0.523
  25                                   sp\|P50336\|PPOX_HUMAN    Protoporphyrinogen oxidase                                          0.529
  26                                   sp\|P02788\|TRFL_HUMAN    Lactotransferrin                                                    0.543
  27                                   sp\|P68872\|HBB_PANPA     Hemoglobin subunit β                                                0.548
  28                                   sp\|Q9Y6W5\|WASF2_HUMAN   Wiskott-Aldrich syndrome protein family member 2                    0.549
  29                                   sp\|P18428\|LBP_HUMAN     Lipopolysaccharide-binding protein                                  0.556
  30                                   sp\|Q99798\|ACON_HUMAN    Aconitate hydratase, mitochondrial                                  0.556

Ratios with P\<0.05 and fold-change \>1.2 were considered to be statistically significant. The top 30 proteins that were increased or decreased in LF according to iTRAQ were extracted. LF, liver failure; iTRAQ, isobaric tags for relative and absolute quantitation.

###### 

Up- and downregulated protein annotation terms of the GO molecular function, cellular component and biological process categories in LF.

  Term                                                    P-value       Term                                                                                                    P-value
  ------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------- -------------
  Biological process                                                                                                                                                            
    Transport                                             6.41E-05      Multi-organism process                                                                                  0.001086326
    Establishment of localization                         6.58E-05      DNA damage response, signal transduction by p53 class mediator                                          0.001163164
    Immune system process                                 0.000134159   Vesicle-mediated transport                                                                              0.001412972
    Immune response                                       0.000164528   Intracellular transport                                                                                 0.001540664
    Establishment of localization in cell                 0.000176366   Release of sequestered calcium ion into cytosol                                                         0.001593621
    Negative regulation of molecular function             0.000205286   Regulation of sequestering of calcium ion                                                               0.001593621
    Negative regulation of catalytic activity             0.000304827   Negative regulation of sequestering of calcium ion                                                      0.001593621
    Localization                                          0.000494539   Cytosolic calcium ion transport                                                                         0.001593621
    Vesicle fusion                                        0.00085815    Calcium ion transport into cytosol                                                                      0.001593621
    Cellular localization                                 0.000951991   Signal transduction by p53 class mediator                                                               0.001850301
  Molecular function                                                                                                                                                            
    Cation transmembrane transporter activity             0.000354884   endopeptidase regulator activity                                                                        0.006225752
    Hydrogen ion transmembrane transporter activity       0.001472303   Immunoglobulin binding                                                                                  0.006472871
    Inorganic cation transmembrane transporter activity   0.002536343   Substrate-specific transmembrane transporter activity                                                   0.006837942
    Peptidase regulator activity                          0.002777008   Endopeptidase inhibitor activity                                                                        0.007710339
    Transporter activity                                  0.003623169   Peptidase inhibitor activity                                                                            0.007710339
    Peptide transporter activity                          0.004093554   Monosaccharide binding                                                                                  0.008311587
    Amide transmembrane transporter activity              0.004093554   Ubiquinol-cytochrome-c reductase activity                                                               0.008525874
    Enzyme inhibitor activity                             0.004329426   Ferric iron binding                                                                                     0.008525874
    Substrate-specific transporter activity               0.004897002   Oxidoreductase activity, acting on diphenols and related substances as donors                           0.008525874
    Ion transmembrane transporter activity                0.005584917   Oxidoreductase activity, acting on diphenols and related substances as donors, cytochrome as acceptor   0.008525874
  Cellular component                                                                                                                                                            
    Cytoplasmic vesicle                                   0.000318      Phagocytic vesicle                                                                                      0.003696
    Vesicle                                               0.000409      endosomal part                                                                                          0.005078
    Cytoplasmic membrane-bounded vesicle                  0.000483      Proteasome complex                                                                                      0.005818
    Secretory granule                                     0.000497      Endosome                                                                                                0.006978
    Cytoplasmic vesicle part                              0.000632      Proteasome core complex, alpha-subunit complex                                                          0.008175
    Membrane-bounded vesicle                              0.000705      TAP complex                                                                                             0.00878
    Platelet alpha granule                                0.00168       Cytoplasmic vesicle membrane                                                                            0.009488
    Secondary lysosome                                    0.002441      Endosome membrane                                                                                       0.010481
    Phagolysosome                                         0.002441      Vesicle membrane                                                                                        0.011522
    Endocytic vesicle                                     0.002743      Organelle envelope lumen                                                                                0.011583

P\<0.05 was considered to be statistically significant. The top 20 GO terms were listed in LF according to molecular function, cellular component and biological process. GO, Gene Ontology; LF, liver failure.

###### 

The Kyoto Encyclopedia of Genes and Genomes pathways of the differently expressed proteins in liver failure.

  Pathway                                       P-value        Pathway ID
  --------------------------------------------- -------------- ------------
  Spliceosome                                   0.0004265046   ko03040
  Cardiac muscle contraction                    0.0006583187   ko04260
  Proteasome                                    0.002674917    ko03050
  Oxidative phosphorylation                     0.004688983    ko00190
  Parkinson\'s disease                          0.0061224      ko05012
  Valine, leucine and isoleucine biosynthesis   0.008369825    ko00290
  Malaria                                       0.01015188     ko05144
  Pathogenic *Escherichia coli* infection       0.0161563      ko05130
  Leukocyte transendothelial migration          0.01934782     ko04670
  Alzheimer\'s disease                          0.01948298     ko05010
  Glycolysis/gluconeogenesis                    0.02570021     ko00010
  Osteoclast differentiation                    0.02836594     ko04380
  Phagosome                                     0.02839378     ko04145
  Galactose metabolism                          0.0475115      ko00052

P\<0.05 was considered to indicate a statistically significant difference.

###### 

Western blot analysis of APEH, WBP2, resistin and TUBB2A in the LF and control groups.

  Name       Control (relative expression)   LF (relative expression)
  ---------- ------------------------------- --------------------------
  Resistin   1.000                           0.715
  APEH       1.000                           1.297
  TUBB2A     1.000                           0.738
  WBP2       1.000                           1.072

APEH, acylaminoacyl-peptide hydrolase; WBP2, WW domain binding protein 2; TUBB2A, tubulin β 2A class IIa; LF, liver failure.

[^1]: Contributed equally
